Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- SKYE +19%, MNDY +8.3%, NIU +5.5%, BORR +5% (revs guidance), BEKE +4.1%, APGE +3.7%, CDRE +3.4%, GOLD +2.4%
Other news:
- KEY +15.3% (receives strategic minority investment from Scotiabank)
- ASND +6.5% (FDA Approves YORVIPATH (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults)
- TBRG +4.9% (files to delay 10-Q; has determined that it will prepare and file amendments to the 2023 Form 10-K and the Q1 2024 Form 10-Q in order to disclose the material weakness in internal controls)
- ZI +3.3% (CEO bought 1,500,000 shares at $8.17 - $8.70 worth approx. $12.7 mln)
- LTRX +3.3% (enters cooperation agreement with 180 Degree Capital Corp)
- SBUX +2.5% (report that activist investor Starboard Value has a stake, according to WSJ)
- AIOT +2.3% (to delay 10-Q filing)
- SMLR +2.1% (files $150 mln mixed shelf securities offering)
- WRN +1.9% (provides Yukon Environmental update)
- RKLB +1.7% (successfully completes latest launch with Capella Space)
- CGNT +1.5% (sends letter to shareholders, urging shareholders to reject Value Base Fund's director nominee)
- SNDX +1% (Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib)